Current options of treatment of hyponatremia

Czech version

Authors: Vladimír Tesař
Authors‘ workplace: Klinika nefrologie 1. LF UK a VFN v Praze
Published in: Vnitř Lék 2016; 62(Suppl 6): 97-101
Category: Reviews

Overview

During the past 50 years the molecular mechanisms of renal reabsorption of sodium and water have been described and molecules specifically interfering with these mechanisms have been developed (diuretics, vasopressin receptor antagonists). Chronic hyponatremia is caused by relative excess of free water, it occurs within a broad spectrum of diseases associated with hypervolemia (heart failure, liver cirrhosis), normovolemia and hypovolemia and it is a negative prognostic factor for patients with chronic heart failure and cirrhotic ascites. Vaptans (vasopressin antagonists, vasopressin V2-receptor inhibitors) reduce reabsorption of water in the distal nephron, they increase free water excretion and normalize serum concentrations of sodium in normovolemic and hypervolemic conditions associated with hyponatremia. Hyponatremia can be corrected (depending on cause, severity and speed of development) through the reduction of fluid intake, administration of a hypertonic solution NaCl, diuretics, oral administration of urea and by vaptans. The role of vaptans in the treatment of hyponatremia should be defined even better, in Europe vaptans can be used to treat the syndrome of inadequate antidiuretic hormone secretion (SIADH).

Key words:
hyponatremia – liver cirrhosis – heart failure – syndrome of inadequate secretion ADH – tolvaptan – vasopressin

Sources

1. Peitzman SJ. The flame photometer as engine of nephrology: a biography. Am J Kidney Dis 2010; 56(2): 379–386. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2010.02.343>.

2. Giebisch G. Coupled ion and fluid transport in the kidney. N Engl J Med 1972; 2878(18): 913–919.

3. Schrier RW, De Wardener HE. Tubular reabsorption of sodium ion: influence of factors other then aldosterone and glomerular filtration rate. First part. N Engl J Med 1971; 285(22): 1231–1243.

4. Palmer LG, Schnermann J. Integrated control of Na transport along the nephron. Clin J Am Soc Nephrol 2015; 10(4): 676–687. Dostupné z DOI: <http://dx.doi.org/10.2215/CJN.12391213>.

5. Bradley SE. Modern concepts of renal structure and function in chronic Bright´s disease. N Engl J Med 1944; 231: 421–426. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM194409212311205>.

6. Eknoyan G. A history of diabetes insipidus: paging the road to internal water balance. Am J Kidney Dis 2010; 56(6): 1175–1183. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2010.08.002>.

7. Agre P, Sasaki S, Chrispels MJ. Aquaporins: a family of water channel proteins. Am J Physiol 1993; 265(3 Pt 2): F461.

8. Knepper MA, Kwon TH, Nielsen S. Molecular physiology of water balance. N Engl J Med 2015; 372(14): 1349–1358. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra1404726>.

9. Spasovski G, Vanholder R, Allolio B et al. Clinical practice guideline on diagnosis and treatment of hyponatremia. Nephrol Dial Transplant 2014; 29(Suppl 2): i1-i39. Dostupné z DOI: <http://dx.doi.org/10.1093/ndt/gfu040>.

10. Allen LA, Gheorghiade M, Reid KJ et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes 2011; 4(4): 389–398. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCOUTCOMES.110.958009>.

11. Kim WR, Biggins SW, Kremers WK et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359(10): 1018–1026. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0801209>.

12. Ahluwalia V, Heuman DM, Feldman G et al. Correction of hyponatremia improves cognition, quality of life, and brain oedema in cirrhosis. J Hepatol 2015; 62(1): 75–82.10. Dostupné z DOI: <http://dx.doi.org/1016/j.jhep.2014.07.033>.

13. Rosner MH. Lixivaptan: a vasopressin receptor antagonist for the treatment of hyponatremia. Kidney Int 2012; 82(11): 1154–1156. Dostupné z DOI: <http://dx.doi.org/10.1038/ki.2012.317>.

14. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342(21): 1581–1589.

15. Sterns RH. Disorders of plasma sodium – causes, consequences, and correction. N Engl J Med 2015; 372(1): 55–65. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra1404489>.

16. Sterns RH, Riggs JE, Schochet SS Jr. Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 1986; 314(24): 1535–1542.

17. Schier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355(20): 2099–2112.

18. Berl T, Quittnat-Pelletier F, Verbalis JG et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21(4): 705–712. Dostupné z DOI: <http://dx.doi.org/10.1681/ASN.2009080857>.

19. Verbalis JG, Adler S, Schrier RW et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 2011; 164(5): 725–732. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-10–1078>.

20. Salahudeen AK, Ali N, George M et al. Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety. Cancer 2014; 120(5): 744–751. Dostupné z DOI: <http://dx.doi.org/10.1002/cncr.28468>.

21. Soupart A, Coffernils M, Couturier B et al. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clin J Am Soc Nephrol 2012; 7(5): 742–747. Dostupné z DOI: <http://dx.doi.org/10.2215/CJN.06990711>.

22. Suzuki S, Yoshihisa A, Yamaki T et al. Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol 2013; 53(12): 1277–1285. Dostupné z DOI: <http://dx.doi.org/10.1002/jcph.197>.

23. Konstam MA, Gheorghiade M, Burnett JC Jr et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297(12): 1319–1331.

24. Hauptman PJ, Burnett J, Gheorghiade M et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail 2013; 19(6): 390–397. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cardfail.2013.04.001>.

25. Verbalis JG, Grossman A, Hoybye C et al. Review and analysis of differing regulatory indications and expert panel guidelines for the treatment of hyponatremia. Curr Med Res Oppin 2014; 30(7): 1201–1207. Dostupné z DOI: <http://dx.doi.org/10.1185/03007995.2014.920314>.

26. Verbalis JG, Goldsmith SR, Greenberg A et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 2013; 126(10 Suppl 1): S1-S42. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2013.07.006>.

27. Aylwin S, Burst V, Peri A et al. Dos and don´ts in the management of hyponatremia. Curr Med Res Opin 2015; 31(9): 1755–1761. Dostupné z DOI: <http://dx.doi.org/10.1185/03007995.2015.1072706>.

28. Gross P. Treatment of hyponatremia. Intern Med 2008; 47(10): 885–891.